ClinicalTrials.gg
WithdrawnNCT06709300Updated Jul 11, 2025

An Observational Study to Evaluate the ETX-4143 Device in Subjects With Ocular Hypertension

An observational study in Ocular Hypertension, sponsored by EyeCool Therapeutics, Inc.. Withdrawn at 1 site in Australia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by EyeCool Therapeutics, Inc. · Observational

How we know

Why this study was withdrawn
Executive decision by the company not to execute the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Ocular Hypertension with a site in Australia — none open to participants now, 2 under way, none of them phase 3. Ocular Hypertension · Australia.

Started
2026
the only one that year
Observational
Only one
of the 14
Registered
12th of 14
by date
Lead sponsor
1 of 14
EyeCool Therapeutics, Inc.

Among the 14 studies in Ocular Hypertension with a site in Australia, this one is the only one that started in 2026, is the only observational one, and was the 12th registered.

Ocular Hypertension

659 studies on the registry are indexed under Ocular Hypertension; 48 are open to participants now.

Browse Ocular Hypertension studies →

Open to participants now

None of the 14 studies in Ocular Hypertension with a site in Australia is open now. The open studies under Ocular Hypertension, anywhere →

Who these studies take

Of the 36 Ocular Hypertension studies recruiting now, 31 (86%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Ocular Hypertension with a site in Australia as a file.
02

Study summary

This study aims to assess the effectiveness of the EyeCool ETX-4143 device in reducing intraocular pressure (IOP) in eyes with ocular hypertension, regardless of a formal diagnosis of primary open-angle glaucoma. The primary objective is to determine whether the EyeCool device can effectively lower IOP in individuals with elevated eye pressure. Participants currently using intraocular pressure-lowering medications but still experiencing elevated IOP may also be eligible to participate.

Read the detailed description

This is a prospective feasibility study designed to evaluate the safety and effectiveness of the EyeCool ETX-4143 device in lowering intraocular pressure (IOP) in eyes with ocular hypertension.

Elevated IOP can negatively affect the optic nerve, often resulting from various clinical conditions. The progression of IOP elevation is typically gradual and painless, which may lead to it going unnoticed by the patient. If left untreated, significantly elevated IOP can cause permanent visual field reduction and vision loss.

Ocular hypertension may occur with or without a formal diagnosis of primary open-angle glaucoma. Additionally, individuals with ocular hypertension may or may not be on ocular hypotensive medications to manage their condition.

This exploratory study aims to determine whether treatment with the EyeCool device results in a safe and effective reduction in IOP. Up to 30 eyes with ocular hypertension will be enrolled and followed for 12 weeks after treatment.

If both eyes meet the inclusion and exclusion criteria, only the eye with the higher IOP will be treated. Participants will not be required to discontinue or modify their use of IOP-lowering medications during the study.

Study findings are expected to inform the design of future clinical trials assessing the ETX-4143 device for the treatment of elevated IOP.

03

Conditions studied

  • Ocular Hypertension

Keywords

  • Ocular Hypertension
  • intraocular pressure
  • Elevated IOP
  • Eye Diseases
  • Glaucoma
  • Raised intraocular pressure
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals that have been diagnosed with hypertension and are seen in the general patient population of an ophthalmic primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients age ≥40 years of age of any gender
  2. Has been diagnosed with elevated IOP (all readings should be taken within the same 4hr daytime window) with a reading of > 21mm Hg in the eye to be studied.
  3. Is either not being treated for elevated IOP or is using ocular hypotensive medication to control IOP.
  4. Have an open angle of the anterior chamber with evidence of trabecular meshwork visible on gonioscopy
  5. Willing to forgo participation in any other clinical study for the duration of this study
  6. Demonstrate sufficient cognitive awareness to comply with the examination process
  7. Willing and able to comply with schedule for follow-up visits
  8. Willing to participate in the study as evidenced by signing of an document

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study time period, including the follow-up period
  2. Known allergy or to copper, aluminum, or silicone
  3. Have previously undergone penetrating intraocular glaucoma surgeries (e.g., glaucoma filtering surgery, trabeculectomy, or tube bypass) in any quadrant of the study eye
  4. Have undergone laser trabeculoplasty (, MLT, or SLT, or cilio-ablative therapy such as cyclophotocoagulation (CPC)) within 90 days prior to starting the study
  5. Any active ocular infection (bacterial, viral, or fungal), or active ocular inflammation at the time of the Screening Visit (note- potential subjects can return for rescreening at a later date after the infection or inflammation has resolved.)
  6. History of corneal transplant (penetrating keratoplasy or endothelial keratoplasty), significant corneal endothelial disease, keratoconus, corneal thinning, or other corneal ectasias
  7. A history of herpes keratitis, non-healing corneal epithelial defects, or neurotrophic keratopathy due to corneal herpetic disease, stem cell deficiency, diabetic keratopathy, severe lagophthalmos, topical anesthetic abuse, or any other cause
  8. Any history of significant conjunctival surgery within the prior 90 days such as pterygium removal, or any presence of any subconjunctival implant (scleral buckle surgery).
  9. Planned eye surgery or other ophthalmic procedures within 90 days following treatment.
  10. Participation in any clinical study of an product within 30 days prior to enrollment
  11. Any history of serious, poorly controlled systemic or ophthalmic condition or circumstances, including those identified in the screening visit which, in the opinion of the Investigator, could compromise the subject's ability to comply with the protocol or that could compromise the subject's safety or the interpretation of the clinical trial results.
  12. Neuropsychiatric disorder (e.g. psychosis, schizophrenia, mania, depression) or major psychiatric illness that has required hospitalization within the last 6 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Study Cohort

    Open-label treatment group with the EyeCool ETX-4143 device in eyes with ocular hypertension that meet the inclusion/exclusion criteria

06

What researchers measure

Primary outcomes

  1. Individual percent reduction in IOP

    Individual percent reduction in intraocular pressure at each post-treatment exam compared to baseline while maintaining the same concomitant ocular hypotensive medication regimen, if any.

    Time frame: From treatment to the end of twelve weeks

  2. Mean reduction in intraocular pressure

    Mean reduction in IOP at each post-treatment exam compared to baseline while maintaining the same concomitant ocular hypotensive medication regime, if any.

    Time frame: From treatment to the end of twelve weeks

07

Study locations

1 site
  • Ophthalmic Trials Australia
    Brisbane, Queensland 4005, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jun 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Nov 29, 2024
StartEst.
Jan 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jul 2026
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06709300
Lead sponsor
EyeCool Therapeutics, Inc.
Collaborators
EyeCool Therapeutics, Pty Ltd
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Jan 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 11, 2025

Study contacts

Patrick R Casey, OD
study chair · EyeCool Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion